| [1] |
PRIETO LI, BAKER DJ. Cellular Senescence and the Immune system in cancer[J]. Gerontology, 2019, 65(5): 505-512. DOI: 10.1159/000500683. |
| [2] |
COGDILL AP, ANDREWS MC, WARGO JA. Hallmarks of response to immune checkpoint blockade[J]. Br J Cancer, 2017, 117(1): 1-7. DOI: 10.1038/bjc.2017.136. |
| [3] |
BRAHMER JR, LACCHETTI C, SCHNEIDER BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2018, 36(17): 1714-1768. DOI: 10.1200/JCO.2017.77.6385. |
| [4] |
PUZANOV I, DIAB A, ABDALLAH K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group[J]. J Immunother Cancer, 2017, 5(1): 95. DOI: 10.1186/s40425-017-0300-z. |
| [5] |
ANDERSON MA, KURRA V, BRADLEY W, et al. Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography[J]. Br J Radiol, 2021, 94(1118): 20200663. DOI: 10.1259/bjr.20200663. |
| [6] |
HUA YW, ZHAO L. Diagnosis and management of immunotherapy-related liver toxicity[J]. Med J Peking Union Med Coll Hosp, 2021, 12(5): 798-806. DOI: 10.12290/xhyxzz.2021-0138. |
| [7] |
GELSOMINO F, VITALE G, D'ERRICO A, et al. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury[J]. Ann Oncol, 2017, 28(3): 671-672. DOI: 10.1093/annonc/mdw649. |
| [8] |
KAWAKAMI H, TANIZAKI J, TANAKA K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer[J]. Invest New Drugs, 2017, 35(4): 529-536. DOI: 10.1007/s10637-017-0453-0. |
| [9] |
GELSOMINO F, VITALE G, ARDIZZONI A. A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event[J]. Invest New Drugs, 2018, 36(1): 144-146. DOI: 10.1007/s10637-017-0484-6. |
| [10] |
PI B, WANG J, TONG Y, et al. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management[J]. Eur J Gastroenterol Hepatol, 2021, 33(Suppl 1): e858-e867. DOI: 10.1097/MEG.0000000000002280. |
| [11] |
CHEUNG V, GUPTA T, PAYNE M, et al. Immunotherapy-related hepatitis: real-world experience from a tertiary centre[J]. Frontline Gastroenterol, 2019, 10(4): 364-371. DOI: 10.1136/flgastro-2018-101146. |
| [12] |
MIZUNO K, ITO T, ISHIGAMI M, et al. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies[J]. J Gastroenterol, 2020, 55(6): 653-661. DOI: 10.1007/s00535-020-01677-9. |
| [13] |
KASHIMA J, OKUMA Y, SHIMIZUGUCHI R, et al. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report[J]. Cancer Immunol Immunother, 2018, 67(1): 61-65. DOI: 10.1007/s00262-017-2062-3. |
| [14] |
COHEN JV, DOUGAN M, ZUBIRI L, et al. Liver biopsy findings in patients on immune checkpoint inhibitors[J]. Mod Pathol, 2021, 34(2): 426-437. DOI: 10.1038/s41379-020-00653-1. |
| [15] |
LAKEHAL F, WENDUM D, BARBU V, et al. Phase Ⅰ and phase Ⅱ drug-metabolizing enzymes are expressed and heterogeneously distributed in the biliary epithelium[J]. Hepatology, 1999, 30(6): 1498-1506. DOI: 10.1002/hep.510300619. |
| [16] |
HARADA K, NAKANUMA Y. Biliary innate immunity in the pathogenesis of biliary diseases[J]. Inflamm Allergy Drug Targets, 2010, 9(2): 83-90. DOI: 10.2174/187152810791292809. |
| [17] |
VISENTIN M, LENGGENHAGER D, GAI Z, et al. Drug-induced bile duct injury[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1498-1506. DOI: 10.1016/j.bbadis.2017.08.033. |
| [18] |
FITZGERALD KA, KAGAN JC. Toll-like receptors and the control of immunity[J]. Cell, 2020, 180(6): 1044-1066. DOI: 10.1016/j.cell.2020.02.041. |
| [19] |
HARADA K, ISSE K, NAKANUMA Y. Interferon gamma accelerates NF-kappaB activation of biliary epithelial cells induced by Toll-like receptor and ligand interaction[J]. J Clin Pathol, 2006, 59(2): 184-190. DOI: 10.1136/jcp.2004.023507. |
| [20] |
HARADA K, van de WATER J, LEUNG PS, et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset[J]. Hepatology, 1997, 25(4): 791-796. DOI: 10.1002/hep.510250402. |
| [21] |
HARADA K, ISSE K, SATO Y, et al. Endotoxin tolerance in human intrahepatic biliary epithelial cells is induced by upregulation of IRAK-M[J]. Liver Int, 2006, 26(8): 935-942. DOI: 10.1111/j.1478-3231.2006.01325.x. |
| [22] |
HARADA K, ISSE K, KAMIHIRA T, et al. Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis[J]. Hepatology, 2005, 41(6): 1329-1338. DOI: 10.1002/hep.20705. |
| [23] |
GUDNASON HO, BJÖRNSSON HK, GARDARSDOTTIR M, et al. Secondary sclerosing cholangitis in patients with drug-induced liver injury[J]. Dig Liver Dis, 2015, 47(6): 502-507. DOI: 10.1016/j.dld.2015.03.002. |
| [24] |
TAKINAMI M, ONO A, KAWABATA T, et al. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis[J]. Invest New Drugs, 2021, 39(6): 1716-1723. DOI: 10.1007/s10637-021-01136-z. |
| [25] |
MEKKI A, DERCLE L, LICHTENSTEIN P, et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1[J]. Eur J Cancer, 2018, 96: 91-104. DOI: 10.1016/j.ejca.2018.03.006. |
| [26] |
ZEN Y, CHEN YY, JENG YM, et al. Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes[J]. Histopathology, 2020, 76(3): 470-480. DOI: 10.1111/his.14000. |
| [27] |
RASCHI E, MAZZARELLA A, ANTONAZZO IC, et al. Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA adverse event reporting system[J]. Target Oncol, 2019, 14(2): 205-221. DOI: 10.1007/s11523-019-00632-w. |
| [28] |
European Association for the Study of the Liver. EASL clinical practice guideline: Occupational liver diseases[J]. J Hepatol, 2019, 71(5): 1022-1037. DOI: 10.1016/j.jhep.2019.08.008. |
| [29] |
LIM JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings[J]. AJR Am J Roentgenol, 2003, 181(3): 819-827. DOI: 10.2214/ajr.181.3.1810819. |
| [30] |
von FIGURA G, STEPHANI J, WAGNER M, et al. Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel[J]. Endoscopy, 2009, 41(Suppl 2): E153- E154. DOI: 10.1055/s-0029-1214707. |
| [31] |
THOMPSON JA, SCHNEIDER BJ, BRAHMER J, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(4): 387-405. DOI: 10.6004/jnccn.2022.0020. |
| [32] |
SUZMAN DL, PELOSOF L, ROSENBERG A, et al. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents[J]. Liver Int, 2018, 38(6): 976-987. DOI: 10.1111/liv.13746. |
| [33] |
ITO T, ISHIGAMI M, YAMAMOTO T, et al. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies[J]. Hepatol Int, 2021, 15(5): 1278-1287. DOI: 10.1007/s12072-021-10238-y. |
| [34] |
WANG HP. Adverse reactions associated with immune checkpoint inhibitor in treatment of liver cancer and related treatment measures[J]. J Clin Hepatol, 2022, 38(5): 985-991. DOI: 10.3969/j.issn.1001-5256.2022.05.003. |
| [35] |
SATO K, HAYASHI M, ABE K, et al. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report[J]. Clin J Gastroenterol, 2020, 13(6): 1310-1314. DOI: 10.1007/s12328-020-01178-5. |
| [36] |
DOHERTY GJ, DUCKWORTH AM, DAVIES SE, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury[J]. ESMO Open, 2017, 2(4): e000268. DOI: 10.1136/esmoopen-2017-000268. |
| [37] |
MCCLURE T, CUI W, ASADI K, et al. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up[J]. BMJ Open Gastroenterol, 2020, 7(1): e000487. DOI: 10.1136/bmjgast-2020-000487. |
| [38] |
OOI R, TOBINO K, SAKABE M, et al. A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis[J]. Respir Med Case Rep, 2020, 31: 101197. DOI: 10.1016/j.rmcr.2020.101197. |
| [39] |
ROMA MG, TOLEDO FD, BOAGLIO AC, et al. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications[J]. Clin Sci (Lond), 2011, 121(12): 523-544. DOI: 10.1042/CS20110184. |
| [40] |
THOMPSON JA, SCHNEIDER BJ, BRAHMER J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241. DOI: 10.6004/jnccn.2020.0012. |
| [41] |
KATAOKA S, MORIGUCHI M, OKISHIO S, et al. Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case[J]. Clin J Gastroenterol, 2022, 15(2): 467-474. DOI: 10.1007/s12328-022-01590-z. |
DownLoad: